We believe that Ingevity Corporation (NGVT - Free Report) is a solid choice for investors seeking exposure in the chemical space. Strengthening end-market demand for its products, services offered by both its business segments and organic and inorganic efforts bode well.
The stock has been upgraded to a Zacks Rank #1 (Strong Buy) on Oct 6.
Why the Upgrade?
Sentiments are positive for Ingevity, as evident from 17.7% rally in its share price since the beginning of the year. The stock has outperformed 10% gain recorded by the industry it belongs to over the same period.
Also, the stocks’ earnings estimates for 2017 have been revised upward by five analysts while that for 2018 have been raised by four in the last 60 days. Currently, the Zacks Consensus Estimate stands at $2.42 for 2017 and $2.78 for 2018, representing 1.7% and 4.5% increase over their respective 60-day ago estimates.
Ingevity Corporation Price and Consensus
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
We believe that Ingevity Corporation (NGVT - Free Report) is a solid choice for investors seeking exposure in the chemical space. Strengthening end-market demand for its products, services offered by both its business segments and organic and inorganic efforts bode well.
The stock has been upgraded to a Zacks Rank #1 (Strong Buy) on Oct 6.
Why the Upgrade?
Sentiments are positive for Ingevity, as evident from 17.7% rally in its share price since the beginning of the year. The stock has outperformed 10% gain recorded by the industry it belongs to over the same period.
Also, the stocks’ earnings estimates for 2017 have been revised upward by five analysts while that for 2018 have been raised by four in the last 60 days. Currently, the Zacks Consensus Estimate stands at $2.42 for 2017 and $2.78 for 2018, representing 1.7% and 4.5% increase over their respective 60-day ago estimates.
Ingevity Corporation Price and Consensus
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on NGVT - FREE
Get the latest research report on CSWI - FREE
Get the latest research report on ASIX - FREE